ChromaCure

ChromaCure is a biotechnology company focused on discovering and developing first-in-class small molecule therapeutics to address unmet needs in oncology. The company is pioneering inhibitors of a novel target that plays a crucial role in tumor initiation and progression. This research is based on groundbreaking work conducted at the Laboratory of Stem Cells and Cancer of the Blanpain Laboratory, at the Université libre de Bruxelles (ULB). ChromaCure primarily serves the oncology market, targeting pharmaceutical companies and healthcare providers who are in need of advanced cancer treatments. The business model revolves around the development and eventual commercialization of these innovative therapeutics, generating revenue through partnerships, licensing agreements, and direct sales. The company operates in a highly competitive biotechnology sector but benefits from strategic support and funding from Wallonia authorities, positioning it at the forefront of European biotech innovation.

Keywords: oncology, small molecule therapeutics, tumor initiation, tumor progression, biotechnology, cancer treatment, pharmaceutical partnerships, licensing agreements, Wallonia, European biotech.